Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its portfolio addresses critical therapeutic areas including oncology, hematology, immunology, cardiovascular disease, neuroscience, and other medical needs. Key products include Eliquis, which reduces the risk of stroke and systemic embolism in non-valvular atrial fibrillation and treats deep vein thrombosis and pulmonary embolism; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. With approximately 34,100 employees and headquarters in New York, the company generates substantial revenue, reporting trailing twelve-month figures of US$48.03 billion alongside earnings of US$6.04 billion. Bristol-Myers Squibb Company plays a pivotal role in advancing healthcare through its focus on high-unmet-need diseases, contributing to the pharmaceutical industry's efforts in oncology and immunology while maintaining strong financial health evidenced by robust gross margins and dividend capabilities.